نتایج جستجو برای: brafv600e
تعداد نتایج: 835 فیلتر نتایج به سال:
Mutation specific antibodies demonstrate the benefit of merging molecular findings with traditional diagnostic expertise. Whether this approach is of sustainable benefit has to be seen. Convincing data on colon carcinoma will be demonstrated at ESMO 2012 with the conclusion to screen patients for BRAFV600E for enrolment in an upcoming clinical trial combining BRAF and EGFR inhibitors.
Ziel/Aim Restoration of iodine incorporation (redifferentiation) was achieved in previously radioiodine-refractory, unresectable thyroid carcinoma by mitogen-activated protein kinase (MAPK) inhibition. However, redifferentiation unsatisfactory BRAFV600E mutated (BRAF-MUT) thus far. Here we assess safety and efficacy therapy through genotype-guided MAPK-modulation patients with BRAF-MUT or wild ...
We aimed to evaluate the prognostic value of BRAFV600E mutation in a series 127 papillary thyroid carcinoma (PTC) cases as single factor, and synergic interaction with other standard risk factors. was assessed by real-time PCR. Event-free survival (EFS) calculated between date first evaluation occurrence an adverse event or last known status. The prevalence 57.2%. Kaplan–Meier analysis showed s...
Here, we report the case of a patient, diagnosed with BRAFV600E-mutated metastatic malignant melanoma M1a, who achieved a complete metabolic response after 7 months of treatment with the combination of dabrafenib and trametinib. After 31 months, the treatment was interrupted for patient's decision. To date October 2017, 18 months after the interruption of the treatment with the combination of d...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید